|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
PLENARY PAPER
From the Nuffield Department of Orthopaedic Surgery,
University of Oxford, Nuffield Orthopaedic Centre, United Kingdom;
Division of Genomic Medicine, University of Sheffield Medical School,
United Kingdom; Department of Medicine, University of Bristol, United
Kingdom; Department of Hematology and Immunology, Free University
Brussels, Belgium; Department of Biology, University of York, United
Kingdom; Department of Academic Radiology, Royal Hallamshire Hospital,
Sheffield, United Kingdom; and Department of Pathology, Amgen, Thousand
Oaks, CA.
Multiple myeloma is a B-cell malignancy characterized by the
accumulation of plasma cells in the bone marrow and the development of
osteolytic bone disease. The present study demonstrates that myeloma
cells express the critical osteoclastogenic factor RANKL (the ligand
for receptor activator of NF- Multiple myeloma is a B-cell neoplasm
characterized by the clonal expansion of plasma cells in the bone
marrow. A major clinical feature of multiple myeloma is the development
of osteolytic bone lesions characterized by the presence of bone pain,
hypercalcemia, and pathologic fractures. The mechanisms that lead to
the development of myeloma bone disease are unclear. However,
histomorphometric studies have demonstrated that the bone disease is
characterized by an uncoupling of the normal process of bone
remodeling.1-4 Bone resorption is increased and associated
with the presence of increased numbers of osteoclasts, whereas bone
formation is reduced.1-4 This uncoupling of resorption and
formation, in association with an increase in the frequency of bone
remodeling units, leads to rapid bone loss and the development of
osteolytic bone lesions.
The factors responsible for the increase in osteoclast formation are
unclear. Early studies demonstrated that myeloma cell lines and tumor
cells from patients with myeloma were able to produce factors that
could stimulate an increase in osteoclastic bone resorption in
vitro.5,6 However, the specific factors that mediate this
increase in bone resorption remain unclear. Studies have implicated
interleukin-1 The receptor activator of NF- Given the critical nature of this system in normal osteoclast
development, it is likely that diseases characterized by abnormal osteoclastic bone resorption, including multiple myeloma, may alter the
balance of the RANKL system in the local bone marrow microenvironment
in favor of bone resorption. Therefore, the aim of the present study
was to determine whether myeloma cells themselves express RANKL and
whether targeting this system with recombinant OPG could inhibit the
development of osteolytic bone disease induced by myeloma cells in vivo
in a model of established multiple myeloma.
The 5T2MM model
Treatment of 5T2MM-bearing mice with recombinant OPG
Treatment with Fc-OPG or vehicle continued for a further 4 weeks, after which time all animals were killed. The femora, tibiae, and lumbar vertebrae were dissected free of soft tissues and processed for flow cytometric analysis of the bone marrow or fixed in 4% formalin before processing for histologic analysis. Blood samples were also obtained for determination of serum paraprotein concentrations. Reverse transcriptase-polymerase chain reaction analysis of 5T2MM cells Expression of the mRNA for RANKL in purified 5T2MM cells and whole bone marrow was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). Bone marrow from control mice or mice bearing 5T2MM cells was flushed from the tibia and femur, and 5T2MM cells were purified as described previously.29 Purity was determined by staining 5T2MM cells with an anti-idiotype antibody and assessing proportions by flow cytometry (see below). In these studies, populations of 5T2MM cells were shown to be 90% to 95% pure. Total RNA was isolated with TriZol (Life Technologies, Glasgow, United Kingdom), precipitated with isopropanol, and resuspended in diethylpyrocarbonate-treated water. Contaminating DNA was removed by incubating RNA samples with DNase I at 37°C for 1 hour. RNA was reverse transcribed to cDNA using Moloney murine leukemia virus reverse transcriptase (Life Technologies) primed with random hexamers (Pharmacia Biotech, Uppsala, Sweden). PCR was performed under standard conditions with 34 cycles of amplification using Amplitaq DNA polymerase (Applied Biosystems, Cheshire, United Kingdom). Following amplification, products were examined by agarose gel electrophoresis and sequenced to confirm their identity. The primers used to amplify murine RANKL were 5'-CAGAATTGCCCGACCAG-3' and 5'-TCCCATAAAGTCACTCTGTCC-3'.Flow cytometric analysis of 5T2MM cells Expression of RANKL on the surface of 5T2MM cells was determined by flow cytometry. The bone marrow from 5T2MM-bearing mice was flushed from the tibia and femur, and mononuclear cells were stained with an anti-5T2MM idiotype-specific murine monoclonal antibody30 and with goat anti-RANKL (IgG, C-20; Santa Cruz Biotechnology, Santa Cruz, CA). After washing, cells were incubated with rat anti-mouse IgG1 conjugated with phycoerythrin (PE; Becton Dickinson, Mountain View, CA) to identify 5T2MM-positive cells, and with rabbit anti-goat IgG conjugated to fluorescein isothiocyanate (FITC; Sigma Chemical, St Louis, MO) to identify RANKL-positive cells. Purified goat IgG (Sigma, Poole, United Kingdom) isolated from pooled normal goat serum was used as a negative control for goat anti-RANKL staining. Expression of RANKL on 5T2MM idiotype-positive and -negative cells was determined and compared with staining with the appropriate isotype control. All samples were analyzed on a FACSort flow cytometer (Becton Dickinson). Samples were analyzed for their forward and side light scatter, as well as FITC and PE fluorescence. Dead or dying cells and cell debris were excluded using appropriate scatter gating.Radiographic and bone densitometric analysis Femora, tibiae, and lumbar vertebrae were radiographed using a Faxitron x-ray system (Hewlett Packard, McMinnville, OR). X-rays were scanned using a UMAX PowerLook 1100 Scanner (Umax Systems, Willich, Germany). Images were enlarged, and the numbers of lytic bone lesions in the tibiae and femora were counted manually. Total bone mineral density (BMD) of the femur, tibia, and lumbar vertebrae was measured by dual-energy x-ray absorptiometry using a PIXImus scanner (Lunar, Madison, WI) with dedicated small-animal software. The coefficient of variation for femoral BMD, obtained after scanning 30 femurs 5 times each following repositioning between scans, was found to be 2.7%. Total BMD and morphometric indices of cortical bone were also determined in the distal femoral metaphysis by peripheral quantitative computed tomography (pQCT) (Stratec, Pforzheim, Germany). Five 70-µm slices, 3 mm from the distal end of the femur and separated by 1 mm, were analyzed, and the mean total BMD, cortical width, endosteal length, and periosteal length were determined.Histologic and histochemical analysis Tibiae and femora were decalcified in EDTA and embedded in paraffin, and 3-µm sections were cut and stained with hematoxylin and eosin. Cancellous bone area as a proportion of the total area was determined in the distal femoral metaphysis and proximal tibial metaphysis, in an area of 0.64 mm2 and 0.25 mm from the growth plate, using a Leica QWin image analysis system (Leica Microscope Systems, Milton Keynes, United Kingdom). Sections of both tibiae and femora were also stained for the presence of tartrate-resistant acid phosphatase (TRAP) to identify osteoclasts and counterstained with Gill hematoxylin. Because infiltration of the bone marrow by 5T2MM cells resulted in almost complete removal of cancellous bone, only osteoclasts lining corticoendosteal bone surfaces were assessed. The number of osteoclasts present on 3 mm of each corticoendosteal surface, beginning 0.5 mm from the growth plate, was counted (number/mm).Statistical analysis Radiographic, densitometric, and histomorphometric analyses were performed in all 5T2MM-bearing animals (5T2MM + vehicle, n = 14; and 5T2MM + OPG, n = 13). All data are expressed as the mean ± SEM. Comparison between groups was performed by the Mann-Whitney U test.
Myeloma cells express RANKL on the cell membrane RT-PCR analysis of RANKL expression in purified 5T2MM cells (90% to 95%) and normal bone marrow mononuclear cells resulted in the amplification of a single product (Figure 1A). This product was sequenced and confirmed to be RANKL. Flow cytometric analysis of bone marrow mononuclear cells isolated from mice bearing 5T2MM cells demonstrated expression of RANKL on idiotype-positive 5T2MM cells (Figure 1B).
IV injection of 5T2MM myeloma cells leads to the development of osteolytic bone disease 5T2MM myeloma cells were injected into the tail vein of C57BL/KaLwRijHsd mice, and development of the myeloma disease was monitored by measuring serum paraprotein. After 8 weeks, all animals injected with tumor cells had detectable serum paraprotein, confirming the presence of tumor cells. After a further 4 weeks, animals were killed and tissues were removed for examination. Histologic analysis of the distal femur, proximal tibia, and lumbar vertebrae demonstrated that 5T2MM cells had homed to the bone marrow and largely replaced the normal bone marrow (Figure 2A,B). 5T2MM cells were found closely associated with large numbers of TRAP-positive osteoclasts that lined the cancellous bone, when present, and the corticoendosteal bone surface (Figure 2C). The presence of large numbers of TRAP-positive osteoclasts resulted in a significant increase in bone resorption and erosion through the cortex (Figure 2D). These histologic changes were readily detected radiographically as small discrete osteolytic lesions in both the femora and the tibiae (Figure 2E).
Treatment of 5T2MM-bearing mice with OPG prevents the development of lytic bone lesions It is clear that 5T2MM myeloma cells can induce the development of osteolytic bone lesions in vivo. Thus, targeting the RANKL system with specific antagonists may inhibit the development of such lesions. Therefore, we examined the effect of recombinant OPG on the development of myeloma bone disease in mice with established myeloma. As expected, radiographic analysis of control animals (no 5T2MM cells) demonstrated the absence of osteolytic lesions in the tibiae or femora (Figure 3A,D,E). In contrast, mice bearing 5T2MM cells (5T2MM vehicle) had large numbers of lesions in both the tibiae and femora (Figure 3B,D,E). However, treatment of mice bearing 5T2MM cells with OPG resulted in a significant decrease in the numbers of lytic bone lesions induced by 5T2MM cells (Figure 3C-E). The numbers of lesions in both tibiae and femora were reduced from 17.7 ± 2.0 to 1.1 ± 0.3 and 6.2 ± 0.9 to 0.8 ± 0.3, respectively. The numbers of lesions in 5T2MM-bearing mice treated with OPG were not significantly different from those in control, uninjected animals.
Injection of 5T2MM cells caused a significant decrease in cancellous
bone volume in the proximal tibial metaphysis and the distal femoral
metaphysis (Figure 4B,D,E). In many
cases, the presence of 5T2MM resulted in the complete loss of
cancellous bone in the metaphysis. Treatment of mice bearing 5T2MM
cells with OPG resulted in a partial prevention of the decrease in
cancellous bone induced by the presence of 5T2MM cells (Figure 4C-E).
In the tibiae, cancellous bone area in the OPG-treated mice was not significantly different from that in control, uninjected animals (3.0 ± 0.4 and 4.2 ± 1.5, respectively), although in the femora, this remained significantly lower that that observed in uninjected animals (4.2 ± 0.8 and 8.7 ± 1.3, respectively;
P < .05).
The presence of 5T2MM cells in the tibiae and femora was associated
with a significant increase in the numbers of osteoclasts. Because
5T2MM cells caused a dramatic reduction in cancellous bone volume, it
was not possible to assess osteoclasts associated with cancellous bone;
however, infiltration of 5T2MM cells resulted in a significant increase
in the numbers of TRAP-positive osteoclasts present on the
corticoendosteal bone surface. In control animals, few osteoclasts were
found on this surface (Figure 5A,D);
however, in animals injected with 5T2MM cells, large numbers of
TRAP-positive cells were observed (Figure 5B,D). In contrast, when
5T2MM-bearing animals were treated with OPG, there was a complete
absence of osteoclasts in the tibiae (Figure 5C,D) and femora (data not
shown).
Treatment of 5T2MM-bearing mice with OPG is associated with an increase in BMD Bone densitometric analyses demonstrated that OPG treatment of mice with established myeloma not only prevented the development of osteolytic lesions, but also was associated with a significant increase in total BMD. Injection of 5T2MM cells caused a significant decrease in total BMD in tibiae, femora, and lumbar vertebrae (Figure 6). Treatment of mice bearing 5T2MM cells with OPG prevented the decrease in total BMD induced by the presence of 5T2MM cells. BMD was significantly greater in mice bearing 5T2MM cells treated with OPG than in those animals bearing 5T2MM cells and treated with vehicle (Figure 6). Interestingly, OPG treatment resulted in an increase in BMD when compared with control animals (Figure 6). OPG treatment caused a significant increase in femoral total BMD (control 62.8 ± 0.9 versus OPG 66.4 ± 1.34), tibial total BMD (control 47.3 ± 0.7 versus OPG 51.2 ± 0.6), and lumbar vertebral total BMD (control 50.6 ± 0.8 versus OPG 61.7 ± 1.2) (P < .05, P < .005, and P < .001, respectively).
The decrease in total BMD in the femora induced by injection of
5T2MM cells was confirmed by pQCT analysis (Figure
7A). Although treatment with OPG resulted
in a significant increase in total BMD when compared with animals
injected with vehicle, this was not significantly greater than control
(Figure 7A). Morphometric analysis of femoral cortical bone revealed
that injection of 5T2MM cells was associated with a significant
decrease in cortical width that was prevented by treatment with OPG
(Figure 7B). The reduction in cortical width appeared to be the result
of an increase in size of the bone marrow cavity as endosteal length,
but not periosteal length, increased significantly in animals bearing
5T2MM cells (Figure 7C,D). The changes in cortical width and endosteal
length were prevented by treatment with OPG. These data are consistent with the demonstration of increased osteoclast numbers present on the
corticoendosteal surface in mice bearing 5T2MM cells (Figure 5).
Treatment of 5T2MM-bearing mice with OPG is associated with a decrease in serum paraprotein OPG is clearly effective at preventing the development of myeloma bone disease in the 5T2MM model. Because inhibiting bone resorption may result in an alteration in the local bone marrow microenvironment in which 5T2MM cells grow, it is possible that this may modulate the growth and survival of tumor cells in this environment. To indirectly assess the effect of OPG on tumor burden, we determined serum paraprotein concentrations after treatment. The mean paraprotein concentration in 5T2MM-bearing animals treated with vehicle was 0.66 ± 0.06 g/dL. Serum paraprotein concentrations were 25% lower (0.5 ± 0.03 g/dL) in the 5T2MM-bearing animals treated with OPG; however, this was not statistically significant.
RANKL has been reported to play a critical role in normal
osteoclast development. Diseases characterized by the presence of increased osteoclast activity, which include multiple myeloma, may
mediate this effect by altering the balance of the RANKL/RANK/OPG system in the local bone environment in favor of increased bone resorption. In the present study, we used RT-PCR analysis to
demonstrate expression of the mRNA for RANKL in purified 5T2MM murine
myeloma cells. Importantly, flow cytometric analysis confirmed that
idiotype-specific myeloma cells isolated from the bone marrow of mice
with established myeloma stained positively for cell surface RANKL.
These data are consistent with a previous report that demonstrated that
the mRNA for RANKL was also expressed by 5TGM1 cells,34 a
murine myeloma cell line generated from the same strain of mouse as
5T2MM. In addition, we have recently demonstrated that myeloma cells isolated from the bone marrow of patients with myeloma also express RANKL on the cell surface, whereas human myeloma cell lines maintained in vitro express the mRNA for RANKL but do not express RANKL on the
cell surface.35 In these studies, staining of myeloma
cells for RANKL was inhibited by the peptide used to raise the antibody and by soluble recombinant RANKL. This suggests that the RANKL antibody
is binding to RANKL. Taken together, these data suggest that myeloma
cells express RANKL on the cell surface, although interactions in the
local bone marrow microenvironment may be important in promoting
expression. The demonstration that myeloma cells express RANKL raises
the possibility that myeloma cells could promote bone resorption
directly. However, the possibility that these cells promote
osteoclast formation indirectly must also be considered. Indeed, in
vitro studies have demonstrated that murine myeloma cells can
up-regulate RANKL mRNA expression in ST2 stromal cells, a process
dependent on the interaction between the
Injection of 5T2MM cells into the tail vein of recipient C57BL/KaLwRij mice resulted in the homing to, and growth of, 5T2MM cells in the bone marrow. 5T2MM cells completely replaced the normal bone marrow and were found closely associated with TRAP-positive multinucleated osteoclasts. Osteoclasts could be found on cancellous bone surfaces, when present, and were observed to line the corticoendosteal surface. There was no evidence of an increase in osteoclast numbers on periosteal surfaces. The proximity of 5T2MM cells to osteoclasts, and the demonstration that they express RANKL, would support the suggestion that they could promote bone resorption directly. This could be achieved by promoting osteoclast recruitment and differentiation and/or the activity of individual osteoclasts. The increase in osteoclast number was associated with almost complete removal of cancellous bone in both femora and tibiae. In addition, morphometric data obtained by pQCT analysis demonstrated a reduction in cortical bone thickness in animals bearing 5T2MM cells. This decrease in cortical thickness was associated with an increase in endosteal circumference without any corresponding change in periosteal length. This would suggest that growth of 5T2MM results in a local increase in osteoclast formation, the resorption of cancellous bone, and expansion of the marrow cavity, which occurs at the expense of cortical bone. Indeed, at some locations, osteoclastic activity was so pronounced that it resulted in significant resorption into the cortex and the development of lytic bone lesions visible by radiography. Because myeloma cells express RANKL, it is likely that they have the capacity to promote osteoclast formation directly. Inhibiting the interaction between RANKL and RANK on osteoclasts and their precursors therefore represents a therapeutic approach to manage this aspect of myeloma. Treatment of mice with established myeloma with recombinant OPG resulted in a significant reduction in the number of osteolytic lesions observed in both femora and tibiae. Histologic analysis demonstrated that OPG treatment was also associated with a partial preservation of cancellous bone volume. However, OPG did not completely prevent the loss of cancellous bone induced by the presence of 5T2MM cells. This may suggest that treatment only partially inhibited the induction of osteoclast activity or that a proportion of the cancellous bone may have been lost before treatment with OPG. To establish which of these possibilities is more likely, we performed histologic examination of osteoclast numbers. These studies demonstrated that OPG treatment completed inhibited the development of TRAP-positive osteoclasts, suggesting that incomplete inhibition of osteoclast activity is unlikely to account for this discrepancy. This would therefore support the suggestion that a certain amount of cancellous bone had been lost before treatment with OPG. Indeed, it is likely that there would have to be a significant expansion of the tumor clone, and possibly associated cancellous bone loss, before it was possible to detect serum paraprotein. Treatment with OPG was also associated with preservation of total BMD at each of the 3 sites examined when compared with animals injected with tumor cells alone. Interestingly, BMD remained higher in the OPG-treated animals than in uninjected control animals. This suggests that OPG treatment was able to inhibit both the age-related bone loss that is seen in the control animals and the bone loss induced by the 5T2MM myeloma cells. Alternatively, this could reflect an effect of OPG on the growth-related accumulation of primary spongiosa at the growth plate, as is seen in young, rapidly growing animals. In addition to inhibiting the development of myeloma bone disease, OPG treatment resulted in a small decrease in serum paraprotein. Although this was not statistically significant, this raises the possibility that OPG may have either direct or indirect antitumor effects. Further studies are therefore required to establish the effect of inhibiting bone resorption with OPG or other antagonists of the RANKL system on the growth and survival of myeloma cells in the bone marrow microenvironment. The data presented in this study show that myeloma cells express RANKL, a factor critical in normal osteoclast formation. The presence of this molecule on myeloma cells raises the possibility that these cells may be able to stimulate osteoclastic bone resorption directly. Targeting the RANKL/RANK system with recombinant OPG, the soluble decoy receptor, is able to prevent the development of osteolytic bone disease in established myeloma. These observations suggest that OPG may represent a novel approach to the treatment of myeloma bone disease.
We thank Angelo Willems for expert technical assistance.
Submitted April 25, 2001; accepted August 6, 2001.
Supported by the Leukaemia Research Fund, the Medical Research Council (United Kingdom), the Fonds voor Wetenschappelijk (FWO)-Vlaanderen, Onderzoeksraad-Free University Brussels, the Vlaamse Internationale Samenwerkingsprojecten, and the British Council. P.I.C. is a Leukaemia Research Fund Bennett Senior Fellow and K.V. is a postdoctoral fellow of the FWO-Vlaanderen.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Peter I. Croucher, Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Headington, Oxford, OX3 7LD, United Kingdom; e-mail: peter.croucher{at}orthopaedic-surgery.oxford.ac.uk.
1. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology of myeloma-induced bone changes. Br J Haematol. 1982;52:601-610[Medline] [Order article via Infotrieve]. 2. Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest. 1991;88:62-66. 3. Taube T, Beneton MNC, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol. 1992;49:192-198[Medline] [Order article via Infotrieve]. 4. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone. 1994;15:41-49[Medline] [Order article via Infotrieve]. 5. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974;291:1041-1046. 6. Mundy GR, Luben RA, Raisz LG, Oppenheim JJ, Buell DN. Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med. 1974;290:867-871.
7.
Lichtenstein A, Berenson J, Norman D, Chang M-P, Carlile A.
Production of cytokines by bone marrow cells obtained from patients with multiple myeloma.
Blood.
1989;74:1266-1273
8.
Cozzolino F, Torcia M, Aldinucci D, et al.
Production of interleukin 1 by bone marrow myeloma cells.
Blood.
1989;74:380-387 9. Garrett IR, Durie BGM, Nedwin GE, et al. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. N Engl J Med. 1987;317:526-532[Abstract]. 10. Bataille R, Klein B, Jourdan M, Rossi JM, Durie BGM. Spontaneous secretion of tumour necrosis factor-beta by human myeloma cell lines. Cancer. 1989;63:877-880[CrossRef][Medline] [Order article via Infotrieve]. 11. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol. 1988;103:902-910. 12. Borset M, Helseth E, Naume B, Waage A. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol. 1993;85:446-451[Medline] [Order article via Infotrieve]. 13. Sati HI, Greaves M, Apperley JF, Russell RG, Croucher PI. Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma. Br J Haematol. 1999;104:350-357[CrossRef][Medline] [Order article via Infotrieve].
14.
Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A.
Hepatocyte growth factor and its receptor c-Met in multiple myeloma.
Blood.
1996;88:3998-4004
15.
Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A.
Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-Met in human myeloma cell lines.
J Biol Chem.
1996;271:24655-24661
16.
Choi SJ, Cruz JC, Craig F, et al.
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma.
Blood.
2000;96:671-675 17. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic cell function. Nature. 1997;390:175-179[CrossRef][Medline] [Order article via Infotrieve]. 18. Lacey DL, Timms E, Tan H-L, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176[CrossRef][Medline] [Order article via Infotrieve].
19.
Suda T, Takahashi N, Martin TJ.
Modulation of osteoclast differentiation.
Endocr Rev.
1992;13:66-80
20.
Wong BR, Rho J, Arron J, et al.
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.
J Biol Chem.
1997;272:25190-25194 21. Kong Y-Y, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315-323[CrossRef][Medline] [Order article via Infotrieve].
22.
Burgess TL, Qian Y-X, Kaufman S, et al.
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
J Cell Biol.
1999;145:527-538 23. Tsuda E, Goto M, Mochizuki S-I, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997;234:137-142[CrossRef][Medline] [Order article via Infotrieve]. 24. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319[CrossRef][Medline] [Order article via Infotrieve].
25.
Bucay N, Sarosi I, Dunstan CR, et al.
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Genes Dev.
1998;12:1260-1268 26. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998;247:610-615[CrossRef][Medline] [Order article via Infotrieve].
27.
Radl J, De Glopper E, Schuit HR, Zurcher C.
Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice.
J Immunol.
1979;122:609-613 28. Radl J, Croese JW, Zurcher C, vanden Enden-Vieveen MH, de Leeuw AM. Animal model of human disease: multiple myeloma. Am J Pathol. 1988;132:177-181.
29.
Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B.
Insulin like growth factor-1 acts as a chemoattractant for 5T2 multiple myeloma cells.
Blood.
1999;93:235-241 30. Vanderkerken K, De Raeve H, Goes E, et al. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33MM cells in the C57BL/KaLwRij mouse. Br J Cancer. 1997;76:451-460[Medline] [Order article via Infotrieve]. 31. Morony S, Capparelli C, Lee R, et al. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrp and 1,25(OH)2D3. J Bone Miner Res. 1999;14:1478-1485[CrossRef][Medline] [Order article via Infotrieve]. 32. Martin SW, Sommers JS, Watson AM, Young JD, Dunstan CR. The pharmacokinetics and pharmacodynamics of OPG following single dose administration in cynomolgus monkeys [abstract]. J Bone Miner Res. 1999;14(suppl 1):S399. 33. Martin SW, Sommers JS, Holloway D, et al. The pharmacokinetics of OPG following single dose subcutaneous and intravenous administration to healthy post menopausal women [abstract]. J Bone Miner Res. 1999;14(suppl 1):S523.
34.
Oyajobi BO, Traianedes K, Yoneda T, Mundy GR.
Expression of rank ligand (RankL) by myeloma cells requires binding to the bone marrow stromal cells via an 35. Shipman CM, Holen I, Lippitt JM, Vandenberghe E, Croucher PI. Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL [abstract]. Blood. 2000;96:360a. 36. Sordillo EM, Wong BR, Liau DF, et al. Multiple myeloma disrupts the TRANCE/OPG cytokine axis [abstract]. Blood. 2000;96:549a.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. A. Fowler, G. R. Mundy, S. T. Lwin, C. C. Lynch, and C. M. Edwards A murine model of myeloma that allows genetic manipulation of the host microenvironment Dis. Model. Mech., November 1, 2009; 2(11-12): 604 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Sezer Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment Oncologist, March 1, 2009; 14(3): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lamoureux, G. Picarda, L. Garrigue-Antar, M. Baud'huin, V. Trichet, A. Vidal, E. Miot-Noirault, B. Pitard, D. Heymann, and F. Redini Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma Cancer Res., January 15, 2009; 69(2): 526 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Roodman New potential targets for treating myeloma bone disease. Clin. Cancer Res., October 15, 2006; 12(20): 6270s - 6273s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawai, T. Matsuyama, Y. Hosokawa, S. Makihira, M. Seki, N. Y. Karimbux, R. B. Goncalves, P. Valverde, S. Dibart, Y.-P. Li, et al. B and T Lymphocytes Are the Primary Sources of RANKL in the Bone Resorptive Lesion of Periodontal Disease Am. J. Pathol., September 1, 2006; 169(3): 987 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Karadag, M. Zhou, and P. I. Croucher ADAM-9 (MDC-9/meltrin-{gamma}), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the {alpha}vbeta5 integrin Blood, April 15, 2006; 107(8): 3271 - 3278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Fisher, R. J. Thomas-Mudge, J. Elliott, D. K. Hards, N. A. Sims, J. Slavin, T. J. Martin, and M. T. Gillespie Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res., April 1, 2006; 66(7): 3620 - 3628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto and M. Abe Myeloma-Bone Interaction: A Vicious Cycle IBMS BoneKEy, March 1, 2006; 3(3): 8 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Body, T. Facon, R. E. Coleman, A. Lipton, F. Geurs, M. Fan, D. Holloway, M. C. Peterson, and P. J. Bekker A Study of the Biological Receptor Activator of Nuclear Factor-{kappa}B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1221 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boissy, T. L. Andersen, B. M. Abdallah, M. Kassem, T. Plesner, and J.-M. Delaisse Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation Cancer Res., November 1, 2005; 65(21): 9943 - 9952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Rogers and R. Eastell Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yaccoby The Phenotypic Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature, Resilient, and Apoptosis-Resistant Phenotype Clin. Cancer Res., November 1, 2005; 11(21): 7599 - 7606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Corey, L. G. Brown, J. A. Kiefer, J. E. Quinn, T. E.M. Pitts, J. M. Blair, and R. L. Vessella Osteoprotegerin in Prostate Cancer Bone Metastasis Cancer Res., March 1, 2005; 65(5): 1710 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto and M. Abe The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions IBMS BoneKEy, February 1, 2005; 2(2): 7 - 10. [Full Text] [PDF]
|
|
|
|
|
|
M. Abe, K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, T. Hashimoto, S. Kido, T. Oshima, H. Shibata, S. Ozaki, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion Blood, October 15, 2004; 104(8): 2484 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Davis Stuck on the TRAIL of osteoclast differentiation Blood, October 1, 2004; 104(7): 1914 - 1915. [Full Text] [PDF]
|
|
|
|
|
|
G. Zauli, E. Rimondi, V. Nicolin, E. Melloni, C. Celeghini, and P. Secchiero TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF Blood, October 1, 2004; 104(7): 2044 - 2050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Van Valckenborgh, P. I. Croucher, H. De Raeve, C. Carron, E. De Leenheer, S. Blacher, L. Devy, A. Noel, E. De Bruyne, K. Asosingh, et al. Multifunctional Role of Matrix Metalloproteinases in Multiple Myeloma: A Study in the 5T2MM Mouse Model Am. J. Pathol., September 1, 2004; 165(3): 869 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Roodman Mechanisms of Bone Metastasis N. Engl. J. Med., April 15, 2004; 350(16): 1655 - 1664. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Bharti, S. Shishodia, J. M. Reuben, D. Weber, R. Alexanian, S. Raj-Vadhan, Z. Estrov, M. Talpaz, and B. B. Aggarwal Nuclear factor-{kappa}B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis Blood, April 15, 2004; 103(8): 3175 - 3184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Onyia, R. J. S. Galvin, Y. L. Ma, D. L. Halladay, R. R. Miles, X. Yang, T. Fuson, R. L. Cain, Q. Q. Zeng, S. Chandrasekhar, et al. Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 369 - 379. [Abstract] [Full Text]
|
|
|
|
|
|
S. Yaccoby, M. J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model Cancer Res., March 15, 2004; 64(6): 2016 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Cheng, M. Kinosaki, M. Takami, Y. Choi, H. Zhang, and R. Murali Disabling of Receptor Activator of Nuclear Factor-{kappa}B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo J. Biol. Chem., February 27, 2004; 279(9): 8269 - 8277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Heider, I. Zavrski, C. Jakob, C. Fleissner, O. Sezer, A. C. W. Zannettino, B. Pan, A. N. Farrugia, G. J. Atkins, and L. B. To Identification and Clinical Relevance of Receptor Activator of Nuclear Factor {kappa}B Ligand Expression of Myeloma Cells Cancer Res., January 15, 2004; 64(2): 773 - 775. [Full Text] [PDF]
|
|
|
|
|
|
B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Farrugia, G. J. Atkins, L. B. To, B. Pan, N. Horvath, P. Kostakis, D. M. Findlay, P. Bardy, and A. C. W. Zannettino Receptor Activator of Nuclear Factor-{kappa}B Ligand Expression by Human Myeloma Cells Mediates Osteoclast Formation in Vitro and Correlates with Bone Destruction in Vivo Cancer Res., September 1, 2003; 63(17): 5438 - 5445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Choi, T. Oba, N. S. Callander, D. F. Jelinek, and G. D. Roodman AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma Blood, May 15, 2003; 101(10): 3778 - 3783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Heider, C. Langelotz, C. Jakob, I. Zavrski, C. Fleissner, J. Eucker, K. Possinger, L. C. Hofbauer, and O. Sezer Expression of Receptor Activator of Nuclear Factor {kappa}B Ligand on Bone Marrow Plasma Cells Correlates with Osteolytic Bone Disease in Patients with Multiple Myeloma Clin. Cancer Res., April 1, 2003; 9(4): 1436 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer RANK ligand and osteoprotegerin in myeloma bone disease Blood, March 15, 2003; 101(6): 2094 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Shipman and P. I. Croucher Osteoprotegerin Is a Soluble Decoy Receptor for Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo2 Ligand and Can Function as a Paracrine Survival Factor for Human Myeloma Cells Cancer Res., March 1, 2003; 63(5): 912 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Vanderkerken, E. De Leenheer, C. Shipman, K. Asosingh, A. Willems, B. Van Camp, and P. Croucher Recombinant Osteoprotegerin Decreases Tumor Burden and Increases Survival in a Murine Model of Multiple Myeloma Cancer Res., January 15, 2003; 63(2): 287 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot Advances in Biology and Therapy of Multiple Myeloma Hematology, January 1, 2003; 2003(1): 248 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cremer, M.-C. Dieu-Nosjean, S. Marechal, C. Dezutter-Dambuyant, S. Goddard, D. Adams, N. Winter, C. Menetrier-Caux, C. Sautes-Fridman, W. H. Fridman, et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction Blood, November 15, 2002; 100(10): 3646 - 3655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Pratt Molecular aspects of multiple myeloma Mol. Pathol., October 1, 2002; 55(5): 273 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Standal, C. Seidel, O. Hjertner, T. Plesner, R. D. Sanderson, A. Waage, M. Borset, and A. Sundan Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells Blood, September 26, 2002; 100(8): 3002 - 3007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Berenson, B. E. Hillner, R. A. Kyle, K. Anderson, A. Lipton, G. C. Yee, and J. S. Biermann American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma J. Clin. Oncol., September 1, 2002; 20(17): 3719 - 3736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman Multiple Myeloma Hematology, January 1, 2002; 2002(1): 214 - 240. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
B). Injection of 5T2MM myeloma cells
into C57BL/KaLwRij mice resulted in the development of bone disease
characterized by a significant decrease in cancellous bone volume in
the tibial and femoral metaphyses, an increase in osteoclast formation,
and radiologic evidence of osteolytic bone lesions. Dual-energy x-ray
absorptiometry demonstrated a decrease in bone mineral density (BMD) at
each of these sites. Treatment of mice with established myeloma with
recombinant osteoprotegerin (OPG) protein, the soluble decoy receptor
for RANKL, prevented the development of lytic bone lesions. OPG
treatment was associated with preservation of cancellous bone volume
and inhibition of osteoclast formation. OPG also promoted an
increase in femoral, tibial, and vertebral BMD. These data suggest that
the RANKL/RANK/OPG system may play a critical role in the development
of osteolytic bone disease in multiple myeloma and that targeting this
system may have therapeutic potential.
(Blood. 2001;98:3534-3540)
, tumor necrosis factor-
,
